News & Updates

First-line treatment with tislelizumab plus chemotherapy showed better survival outcomes and response among patients with locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC), particularly those with high PD-L1 expression, compared with chemotherapy alone, according to a subgroup analysis of the phase III RATIONALE-304 trial presented at ELCC 2025.

The world’s first artificial intelligence (AI) model for diagnosis of well-differentiated thyroid cancer, developed by researchers from the University of Hong Kong (HKU), has demonstrated high accuracy in staging and risk classification based on analysis of semi-structured free-text clinical notes.

Some of the important treatment options for patients with acute myeloid leukaemia (AML) include chemotherapy, targeted therapy, and immunotherapy, but the efficacy of these treatments may vary depending on AML status, age, and cytogenetic risk, according to a study.

The safety of nivolumab anticancer therapy may be improved through close collaboration between cardiology and oncology specialists, which can help detect cardiac complications early and manage these conditions effectively, suggests a study.

In the final overall survival (OS) analysis of the phase III MIRASOL trial, the survival benefit previously reported with the antibody drug conjugate mirvetuximab soravtansine (MIRV) remains superior to investigator’s choice chemotherapy (ICC) for the treatment of folate receptor alpha-positive, platinum-resistant ovarian cancer (FRα+ PROC).

Gynaecologic oncology patients with better sleep efficiency in the days before a surgical procedure are more likely to have fewer postoperative complications and require lower doses of opioid pain medication upon hospital discharge, according to a study.

Regular physical activity appears to protect against lower extremity lymphedema in endometrial cancer survivors, as reported in a study.

In patients with resectable nonsmall cell lung cancer (NSCLC), adding perioperative durvalumab to neoadjuvant chemotherapy does not appear to have a detrimental impact on patient-reported health-related quality of life (QoL), functioning, or symptoms as compared with neoadjuvant chemotherapy alone, according to data from the phase III AEGEAN study.